Evidence-Based Guidelines to Drive Improved Care for Patients with ITP
Published on: December 03, 2019
(Washington, DC, Dec. 3, 2019) — Today, ASH published new state-of-the art guidelines on the treatment of immune thrombocytopenia (ITP), a rare blood disorder characterized by a decrease in the number of platelets, the part of the blood needed for normal clotting. The guidelines are published in the journal Blood Advances.
The 2019 ASH Clinical Practice Guidelines on ITP, developed in partnership with the University of Oklahoma Health Sciences Center, synthesize all available evidence about existing treatments to offer recommendations for disease management in both children and adults.
- From the American Society of Hematology